新辅助免疫联合化疗治疗在局部晚期食管鳞状细胞癌中的研究进展
Recent Advances in Combination of Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
摘要: 食管癌具有死亡率高、预后差等特点。超过三分之一的患者被诊断为局部晚期癌症。食管鳞状细胞癌(ESCC)是亚洲和东欧食管癌的主要组织学亚型。虽然新辅助或最终放化疗(CRT)已成为局部晚期食管鳞状细胞癌的标准治疗方法，但患者的预后仍然不理想，复发率高达30%~50%。免疫检查点抑制剂(ICI)与化学联合治疗食管鳞状细胞癌已成为一种新策略，可能具有协同作用并提供更高的疗效。一些I期和II期研究表明，ICIs联合同步化疗可能会增加可切除食管鳞状细胞癌的病理完全缓解率，但缺乏长期随访结果。在这篇综述中，我们将描述新辅助免疫联合化学治疗局部晚期食管鳞状细胞癌的基本原理和治疗历程。
Abstract: Esophageal cancer has a high mortality rate and a poor prognosis, with more than one-third of pa-tients receiving a diagnosis of locally advanced cancer. Esophageal squamous cell carcinoma (ESCC) is the dominant histological subtype of esophageal cancer in Asia and Eastern Europe. Although neoadjuvant or definitive chemoradiotherapy (CRT) has been the standard treatment for locally advanced ESCC, patient outcomes remain unsatisfactory, with recurrence rates as high as 30%~50%. The combination of immune checkpoint inhibitors (ICIs) and CRT has emerged as a novel strategy to treat esophageal cancer, and it may have a synergistic action and provide greater efficacy. Moreover, several phase I and II studies have shown that ICIs combined with chemothera-py may increase the rate of pathologic complete response for resectable ESCC, but they lack long-term follow-up results. In this review, we will describe the basic principles and treatment pro-cess of neoadjuvant immunotherapy combined with chemotherapy for locally advanced esophageal squamous cell carcinoma.
文章引用：伊雯, 张莉. 新辅助免疫联合化疗治疗在局部晚期食管鳞状细胞癌中的研究进展[J]. 临床医学进展, 2024, 14(2): 4083-4088. https://doi.org/10.12677/ACM.2024.142567

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Ajani, J.A., D’Amico, T.A., Bentrem, D.J., et al. (2019) Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. The National Comprehensive Cancer Network, 17, 855-883.
[3] Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. [Google Scholar] [CrossRef] 
[4] Luo, H., Lu, J., Bai, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925. [Google Scholar] [CrossRef] [PubMed]
[5] Kojima, T., Shah, M.A., Muro, K., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148. [Google Scholar] [CrossRef] 
[6] Choueiri, T.K., Powles, T., Burotto, M., et al. (2021) Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 384, 829-841.
[7] Wang, Z.X., Cui, C., Yao, J., et al. (2022) Toripalimab plus Chemotherapy in Treatment-Naïve, Ad-vanced Esophageal Squamous Cell Carcinoma (JUPITER-06): A Multi-Center Phase 3 Trial. Cancer Cell, 40, 277-288.E3.
[8] Doki, Y., Ajani, J.A., Kato, K., et al. (2022) Nivolumab Combination Therapy in Advanced Esopha-geal Squamous-Cell Carcinoma. The New England Journal of Medicine, 386, 449-462.
[9] Forde, P.M., Chaft, J.E., Smith, K.N., et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medi-cine, 378, 1976-1986. [Google Scholar] [CrossRef] 
[10] Amaria, R.N., Reddy, S.M., Tawbi, H.A., et al. (2018) Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma. Nature Medicine, 24, 1649-1654. [Google Scholar] [CrossRef] [PubMed]
[11] Schalper, K.A., Rodriguez-Ruiz, M.E., Diez-Valle, R., et al. (2019) Neoadjuvant Nivolumab Modifies the Tumor Immune Microenvironment in Resectable Glioblastoma. Na-ture Medicine, 25, 470-476. [Google Scholar] [CrossRef] [PubMed]
[12] Ledford, H. (2011) Melanoma Drug Wins US Approval. Nature, 471, 561. [Google Scholar] [CrossRef] [PubMed]
[13] Keir, M.E., Liang, S.C., Guleria, I., et al. (2006) Tissue Expression of PD-L1 Mediates Peripheral T Cell Tolerance. Journal of Experimental Medicine, 203, 883-895. [Google Scholar] [CrossRef] [PubMed]
[14] Sun, C., Mezzadra, R. and Schumacher, T.N. (2018) Regulation and Function of the PD-L1 Checkpoint. Immunity, 48, 434-452. [Google Scholar] [CrossRef] [PubMed]
[15] Chowdhury, P.S., Chamoto, K. and Honjo, T. (2018) Combina-tion Therapy Strategies for Improving PD-1 Blockade Efficacy: A New Era in Cancer Immunotherapy. Journal of Inter-nal Medicine, 283, 110-120. [Google Scholar] [CrossRef] [PubMed]
[16] Li, C., Zhao, S., Zheng, Y., et al. (2021) Preoperative Pembrolizumab Combined with Chemoradiotherapy for Oesophageal Squamous Cell Carcinoma (PALACE-1). European Journal of Cancer, 144, 232-241. [Google Scholar] [CrossRef] [PubMed]
[17] Yang, H., Liu, H., Chen, Y., et al. (2018) Neoadjuvant Chemoradi-otherapy Followed by Surgery versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. Journal of Clinical Oncology, 36, 2796-2803.[CrossRef] 
[18] Zheng, Y., Li, C., Yu, B., et al. (2021) Preoperative Pembroli-zumab Combined with Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Trial Design. JTCVS Open, 9, 293-299. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, R., Liu, Q., Li, Q., et al. (2023) A Phase II Clinical Trial of Toripalimab Combined with Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC1901). eClinicalMedicine, 62, Article ID: 102118. [Google Scholar] [CrossRef] [PubMed]
[20] Provencio, M., Nadal, E., Insa, A., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422. [Google Scholar] [CrossRef] 
[21] Zhang, Z., Hong, Z.N., Xie, S., et al. (2021) Neoadjuvant Sintilimab plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Sin-gle-Center, Phase 2 Trial (ESONICT-1). Annals of Translational Medicine, 9, Article 1623. [Google Scholar] [CrossRef] [PubMed]
[22] Yang, P., Zhou, X., Yang, X., et al. (2021) Neoadjuvant Camrelizumab plus Chemotherapy in Treating Locally Advanced Esophageal Squamous Cell Carcinoma Patients: A Pilot Study. World Journal of Surgical Oncology, 19, Article No. 333. [Google Scholar] [CrossRef] [PubMed]
[23] Topalian, S.L., Taube, J.M. and Pardoll, D.M. (2020) Neoadjuvant Checkpoint Blockade for Cancer Immunotherapy. Science, 367, eaax0182. [Google Scholar] [CrossRef] [PubMed]
[24] Xing, W., Zhao, L., Zheng, Y., et al. (2021) The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Ad-vanced Esophageal Squamous Cell Cancer—A Phase II Study. Frontiers in Immunology, 12, Article 772450. [Google Scholar] [CrossRef] [PubMed]
[25] Zheng, Y., Liu, X.B., Sun, H.B., et al. (2021) A Phase III Study on Neoadjuvant Chemotherapy versus Neoadjuvant Toripalimab plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Annals of Trans-lational Medicine, 9, Article 73. [Google Scholar] [CrossRef] [PubMed]
[26] Yamamoto, S., Kato, K., Daiko, H., et al. (2020) Feasibility Study of Nivolumab as Neoadjuvant Chemotherapy for Locally Esophageal Carcinoma: FRONTiER (JCOG1804E). Future On-cology, 16, 1351-1357. [Google Scholar] [CrossRef] [PubMed]

为你推荐